DAY Three #CFS25 🚨
A sea change in Small Cell Lung Cancer (SCLC) treatment is here! Dr. Charles Rudin discusses the shift from traditional chemo to novel agents like bispecific T-cell engagers & ADCs #SCLC #LungCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three of #CFS25 🚨
Stage I-III cancer management is evolving! Dr. Thomas Marron discusses how neoadjuvant and perioperative immunotherapy are now demonstrating a significant OS benefit by targeting micrometastatic disease.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
DAY Three #CFS25 🚨
Incredible progress in MSI-H localized colorectal cancer! Dr. Andrea Cercek's work shows that 82% of non-rectal tumors achieved a clinical complete response with systemic immunotherapy. #ColorectalCancer
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day Three #CFS25 🚨
Precision medicine is transforming GI oncology! Dr. Rona Yaeger dives into targeted strategies for BRAF, KRAS, and HER2 across colorectal, biliary tract, esophageal, and pancreatic cancers, #GIOncology
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
This episode of OncLive On Air was filmed LIVE at #CFS25! Hear @benlevylungdoc.bsky.social & Dr Tagawa highlight developments in GU cancer management. Watch the video on our site, or listen wherever you get your podcasts! @weillcornell.bsky.social #kcsm #pcsm
www.onclive.com/view/psma-th...
DAY Two of #CFS25 🚨
Dr. Vincent Xu breaks down the latest in combination therapy for Renal Cell Carcinoma (RCC). PD-1 based doublets are the standard of care for 1st-line metastatic disease. #KidneyCancer #RCC #CombinationTherapy
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0
Day One of #CFS25 🚨
Should we treat Clonal Hematopoiesis (CH)? Dr. Uma Borate explores refining treatment goals for CHIP and Lower-Risk MDS, noting that CH mutations offer a potential 'window for early intervention' before progression to AML. #MDS #CHIP #Leukemia #Hematology
Day One of #CFS25 🚨
Big changes in CLL management! Dr. John Allan reviews the latest NCCN Guideline updates, fixed-duration doublets and triplets, and overcoming resistance to BTK inhibitors.
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) buff.ly/OWT0DgG
Day One of #CFS25
Now with When should we use CAR-T for early relapsed Multiple Myeloma (RRMM)?
Dr. Noa Biran highlights that unprecedented efficacy, healthier T-cells, and improved quality of life favor early CAR-T, especially for high-risk disease. #MultipleMyeloma #CARTcell #Oncology
